Zydus Lifesciences Ltd Q2 FY26 Earnings Analysis
Published 20 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹1.1L Cr
Price
₹1,104
Market Cap
₹1.1L Cr
P/E Ratio
23.3
How does Zydus Lifesciences Ltd rank in Pharmaceuticals & Biotechnology?
Compare Zydus Lifesciences Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Zydus Lifesciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹7.6K Cr, net profit ₹1.3K Cr.
Full financials →Earnings Summary
US business expects sustained long-term growth with 25+ product launches planned this year; base business remains stable with single-digit price erosion. The company maintains a strong growth momentum with consistent performance across segments, aiming to achieve targeted top-line growth and profitability for the fiscal year.
📊 Revenue & Sales Performance
- →US business expects sustained long-term growth with 25+ product launches planned this year; base business remains stable with single-digit price erosion.
- →Specialty portfolio, including 505(b)(2) injectables like Beizray, to scale meaningfully over next 2-3 years.
- →Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies.
- →Consumer wellness (Comfort Click acquisition) targets strong growth via market expansion in Europe, Middle East, US, and scaling pediatric and pet supplement brands.
- →International formulations business growing in strong double digits, driven by emerging markets and Europe.
- →Vaccine business expected to become a meaningful part of revenue in 2 years; participating in global tenders by FY27-28.
- →Saroglitazar launch in US expected within 14-15 months with a sizeable commercial opportunity.
- →Middleware/Future quarters expect higher US quarterly run rate launches, offsetting generic erosion on certain products.
📈 Profitability & Margins
- →The company maintains a strong growth momentum with consistent performance across segments, aiming to achieve targeted top-line growth and profitability for the fiscal year.
- →US business shows double-digit growth, driven by volume expansion and new product launches, with a focus on specialty and 505(b)(2) products for sustained long-term growth.
- →Indian branded formulations are growing ahead of market with a strong chronic and super specialty portfolio.
- →Consumer wellness segment, boosted by acquisition of Comfort Click, is positioned for high growth, especially in Europe, US, and Middle East.
- →International markets exhibit strong double-digit growth with broad-based demand.
- →Operating profitability remains robust with a consolidated EBITDA margin guidance of 26%+ for the full year, despite a higher first-half margin of ~32%.
- →Specialty and MedTech acquisitions will expand revenue and margin base over medium term.
- →Strategic fundraising aims to deleverage and enable future acquisitions to drive further growth.
- →Overall, expectations are for steady growth in earnings and EBITDA margins across businesses over coming quarters.
🏗️ Capital Expenditure Plans
- →The company is investing in building a nephrology facility to produce high-end membranes for dialysis to meet global demand.
- →Investments were made in acquisitions: Amplitude Surgical (MedTech) and Comfort Click (consumer wellness/D2C platform).
- →There is a strategic focus on expanding the MedTech business in cardiology, nephrology, and orthopedics globally.
- →Future capex includes commissioning new manufacturing facilities like the nephrology one.
- →Plans to scale up Saroglitazar commercialization in the US, which may involve investment in commercial infrastructure, including a 60-80 person field force.
- →Focus on innovation and pipeline expansion in specialty pharma and injectables, which may require capital allocation.
- →Fundraising initiatives aim to deleverage the balance sheet and fund potential acquisitions in US specialty, international markets (Europe), and innovative assets.
- →No immediate MedTech acquisitions planned, but the company remains opportunistic for strategic investments in this area.
💰 Fundraising & Capital Structure
- →The company has approved an enabling Qualified Institutional Placement (QIP) resolution to provide flexibility to raise capital from the markets when required.
- →The key objective of the fundraising initiative is to deleverage the balance sheet by reducing existing debt and to enhance financial ability and agility for future growth.
- →Fundraising proceeds will support scaling up the US specialty business, expanding in international markets (especially Europe), and investing in innovative assets including MedTech.
- →No immediate actionable deal is currently identified; the focus remains on strategic areas like US specialty, international markets, and select brands for India.
- →The management is looking at maintaining net debt to EBITDA below 1x without acquisition and up to 2x temporarily during acquisition before deleveraging again.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Zydus Lifesciences Ltd Q2 FY26 results?
US business expects sustained long-term growth with 25+ product launches planned this year; base business remains stable with single-digit price erosion. The company maintains a strong growth momentum with consistent performance across segments, aiming to achieve targeted top-line growth and profitability for the fiscal year.
What is Zydus Lifesciences Ltd share price analysis?
Zydus Lifesciences Ltd currently shows a neutral. The stock trades at a P/E of 23.3 with a market cap of ₹113,237 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zydus Lifesciences Ltd planning capital expenditure?
The company is investing in building a nephrology facility to produce high-end membranes for dialysis to meet global demand.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.